28 November 2018 | News
The company expects that the product will provide patients and medical professionals with various options for cancer treatment.
Daiichi Sankyo Company, Limited has launched the antitumor agent trastuzumab Biosimilar for intravenous drip infusions 60 mg and 150 mg “Daiichi Sankyo” in Japan.
The product is a pharmaceutical agent developed by Amgen Inc. as a biosimilar product to the anti-HER2 antibody, trastuzumab. The product was approved on September 21, 2018, and indicated for breast cancer with HER2 overexpression (Dosage A), and unresectable advanced or relapsed gastric cancer with HER2 overexpression (Dosage B).
Based on the exclusive agreement on the commercialization of biosimilars concluded with Amgen in July 2016, Daiichi Sankyo is responsible for the distribution and commercialization of the product in Japan, while Amgen is responsible for its manufacture.
The product is the first biosimilar product launched by Daiichi Sankyo, and the company expects that the product will provide patients and medical professionals with various options for cancer treatment, thereby further contributing to medical treatment.